Brought to you by 
Dr. Reddy's gets Indian rights to Galena's NeuVax
16 Nov 2021
Executive Summary
Galena Biopharma Inc. (oncology) licensed Dr. Reddy’s Laboratories Ltd. exclusive rights to develop and sell NeuVax (nelipepimut-S) in India for breast and gastric cancers.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Large Molecule
- Immuno-Oncology
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Dr. Reddy's gets Indian rights to Galena's NeuVax
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice